1. Study name: A prospective study of the incidence and outcomes of Primary aldosteronism in Chinese hypertensive patients 2. Rationale: Unlike essential hypertension, secondary hypertension is caused by certain defined diseases or causes. For this reason, secondary hypertension can often be cured or effectively controlled. As one of the most common types of secondary hypertension, it is estimated that primary aldosteronism (PA) accounts for 5%-10% of all hypertensive patients, accounting for about 20% of patients with refractory hypertension.3. Objective: 1) Collect and analyze the population and disease characteristics of Chinese PA patients; 2) Strengthen the awareness of screening for PA in people with high blood pressure.4. Study design: Prospective , multi-center, observational study.5. Study population: Hypertensive patients with high suspected or confirmed of primary aldosteronism.6. Treatment: Standardized diagnosis and treatment procedure as recommended in the international guidelines of PA.7. Follow up: 6, 12 and 24 months after diagnosis.8. Sample size estimation: About 10 thousand.9. Timeline: Start of subjects enrollment: July 2019; End of subjects enrollment: December 2022; End of study: December 2024.10. Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai, China.
Study Name: Primary Aldosteronism: Prospective Screening Registry in China
Status: Not yet recruiting
Conditions: Primary aldosteronism
Interventions: Observational only
Locations: Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Study link: https://ClinicalTrials.gov/show/NCT04020783
To search for other studies by topic, location, or status, go to our Clinical Studies page.